Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Neubauer, S.; Cifaldi, M.; Mittendorf, T.; Ganguli, A.; Wolff, M.; et al.: Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: persistence and dosing patterns in Germany. In: Health Economics Review 4 (2014), Nr. 1, 32. DOI: https://doi.org/10.1186/s13561-014-0032-4
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Gottfried Wilhelm Leibniz Universität Hannover
- (when)
-
2014
- Event
-
Veröffentlichung
- (where)
-
Hannover
- (who)
-
Technische Informationsbibliothek (TIB)
- (when)
-
2014
- Creator
- DOI
-
10.15488/963
- URN
-
urn:nbn:de:101:1-2020080806550729336032
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Neubauer, Sarah
- Cifaldi, Mary
- Mittendorf, Thomas
- Ganguli, Arijit
- Wolff, Malte
- Zeidler, Jan
- Gottfried Wilhelm Leibniz Universität Hannover
- Technische Informationsbibliothek (TIB)
Time of origin
- 2014
Other Objects (12)
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Long-term remission and biologic persistence rates: 12-year real-world data
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use
TNF-α Regulates Mast Cell Functions by Inhibiting Cell Degranulation
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis
Biologic basis of pigmentation
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Long-term remission and biologic persistence rates: 12-year real-world data
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use
TNF-α Regulates Mast Cell Functions by Inhibiting Cell Degranulation
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis
Biologic basis of pigmentation
Biologic TNF inhibiting agents for treatment of rheumatoid arthritis: Persistence and dosing patterns in Germany
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: Dosing patterns and related costs in Switzerland from a payers perspective
Long-term remission and biologic persistence rates: 12-year real-world data
Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study
Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use
TNF-α Regulates Mast Cell Functions by Inhibiting Cell Degranulation
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis
Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
Fuzheng Huayu recipe alleviates hepatic fibrosis via inhibiting TNF-α induced hepatocyte apoptosis